Most cases are idiopathic. When a cause is identified, viral infections affecting the inner ear, disrupted blood flow to cochlear structures, autoimmune reactions, and physical trauma are the most recognized contributors. No established genetic cause underlies typical sporadic SSNHL, and the condition is not inherited in a Mendelian sense.

Diagnosis is made by audiometric testing documenting hearing loss meeting defined thresholds within a short time window. Evaluation includes clinical history, physical examination, and MRI to exclude structural causes such as auditory nerve lesions. Laboratory testing may evaluate for infectious or inflammatory contributors.

Corticosteroids — administered systemically or by intratympanic injection — are the primary treatment and are most effective when started promptly. Intratympanic delivery is used as both initial and rescue therapy. No FDA-approved drugs are specifically indicated for SSNHL, though three compounds hold orphan drug designation for acute sensorineural hearing loss and are being evaluated in clinical trials.

Recovery varies widely. Partial or complete return of hearing occurs in many individuals, particularly with early treatment. Better outcomes are associated with less severe initial loss, younger age, and absence of vertigo at onset. Persistent hearing loss may be managed with hearing aids or cochlear implants, and ongoing audiological monitoring is recommended.

Over 20 clinical trials are registered for SSNHL, examining novel steroid delivery methods, intracochlear drug administration, and other pharmacological approaches. Three compounds hold FDA orphan drug designation for acute sensorineural hearing loss, reflecting recognized unmet medical need.